Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

David Thompson

Clinical Trial Administrator

 I started at OCTO as a Clinical Trial Support Officer, with no previous experience in clinical trials; however, the position provided me with a great opportunity to start an exciting new career and develop my career skills within a motivating department. OCTO provided regular training sessions and support which enabled me to learn about all aspects of clinical trials, and after 3 years I was promoted to a Clinical Trials Administrator.

I currently work on:

NuTIDE:301: A two-part, Phase 1 open-label dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours. 

I have previously worked on:

AspECT: A Phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia.

CAMELLIA: A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Haematological Malignancies